163 related articles for article (PubMed ID: 32172303)
1. Outcomes of primary endocrine therapy in elderly women with stage I-III breast cancer: a SEER database analysis.
Yuan C; Xie Z; Bian J; Huo J; Daily K
Breast Cancer Res Treat; 2020 Apr; 180(3):819-827. PubMed ID: 32172303
[TBL] [Abstract][Full Text] [Related]
2. Survival Outcomes of Early-Stage Hormone Receptor-Positive Breast Cancer in Elderly Women.
Nayyar A; Strassle PD; Iles K; Jameison D; Jadi J; McGuire KP; Gallagher KK
Ann Surg Oncol; 2020 Nov; 27(12):4853-4860. PubMed ID: 32918178
[TBL] [Abstract][Full Text] [Related]
3. Delayed initiation of adjuvant chemotherapy in older women with breast cancer.
Smith-Graziani D; Lei X; Giordano SH; Zhao H; Karuturi M; Chavez-MacGregor M
Cancer Med; 2020 Oct; 9(19):6961-6971. PubMed ID: 32767723
[TBL] [Abstract][Full Text] [Related]
4. Effect of Age on Breast Cancer Patient Prognoses: A Population-Based Study Using the SEER 18 Database.
Chen HL; Zhou MQ; Tian W; Meng KX; He HF
PLoS One; 2016; 11(10):e0165409. PubMed ID: 27798652
[TBL] [Abstract][Full Text] [Related]
5. Metastatic breast cancer survival improvement restricted by regional disparity: Surveillance, Epidemiology, and End Results and institutional analysis: 1990 to 2011.
Malmgren JA; Calip GS; Atwood MK; Mayer M; Kaplan HG
Cancer; 2020 Jan; 126(2):390-399. PubMed ID: 31639221
[TBL] [Abstract][Full Text] [Related]
6. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
7. Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data.
Lang K; Huang H; Sasane M; Paly VF; Hao Y; Menzin J
BMC Health Serv Res; 2014 Jul; 14():298. PubMed ID: 25008431
[TBL] [Abstract][Full Text] [Related]
8. Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy.
Yu KD; Wu J; Shen ZZ; Shao ZM
J Clin Endocrinol Metab; 2012 Dec; 97(12):E2201-9. PubMed ID: 22993034
[TBL] [Abstract][Full Text] [Related]
9. Impact of NCI Socioeconomic Index on the Outcomes of Nonmetastatic Breast Cancer Patients: Analysis of SEER Census Tract-Level Socioeconomic Database.
Abdel-Rahman O
Clin Breast Cancer; 2019 Dec; 19(6):e717-e722. PubMed ID: 31519450
[TBL] [Abstract][Full Text] [Related]
10. Evaluating Candidacy for Hypofractionated Radiation Therapy, Accelerated Partial Breast Irradiation, and Endocrine Therapy After Breast Conserving Surgery: A Surveillance Epidemiology and End Results (SEER) Analysis.
Manyam BV; Tendulkar R; Cherian S; Vicini F; Badiyan SN; Shah C
Am J Clin Oncol; 2018 Jun; 41(6):526-531. PubMed ID: 27635622
[TBL] [Abstract][Full Text] [Related]
11. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
12. Hormone receptor-negative breast cancer: undertreatment of patients over 80.
Weiss A; Noorbakhsh A; Tokin C; Chang D; Blair SL
Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
[TBL] [Abstract][Full Text] [Related]
14. Racial Differences in Adjuvant Endocrine Therapy Use and Discontinuation in Association with Mortality among Medicare Breast Cancer Patients by Receptor Status.
Farias AJ; Du XL
Cancer Epidemiol Biomarkers Prev; 2017 Aug; 26(8):1266-1275. PubMed ID: 28515111
[No Abstract] [Full Text] [Related]
15. Older Patients With Early-stage Breast Cancer: Adjuvant Radiation Therapy and Predictive Factors for Cancer-related Death.
Nagar H; Yan W; Christos P; Chao KSC; Nori D; Ravi A
Am J Clin Oncol; 2017 Jun; 40(3):300-305. PubMed ID: 25333731
[TBL] [Abstract][Full Text] [Related]
16. Impact of preexisting mental illness on breast cancer endocrine therapy adherence.
Haskins CB; McDowell BD; Carnahan RM; Fiedorowicz JG; Wallace RB; Smith BJ; Chrischilles EA
Breast Cancer Res Treat; 2019 Feb; 174(1):197-208. PubMed ID: 30465157
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness of Chemotherapy Regimens in Prolonging Survival for Two Large Population-Based Cohorts of Elderly Adults with Breast and Colon Cancer in 1992-2009.
Du XL; Zhang Y; Parikh RC; Lairson DR; Cai Y
J Am Geriatr Soc; 2015 Aug; 63(8):1570-82. PubMed ID: 26200214
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Adjuvant Radiation Therapy Alone Versus Radiation Therapy and Endocrine Therapy in Elderly Women With Early-Stage, Hormone Receptor-Positive Breast Cancer Treated With Breast-Conserving Surgery.
Murphy CT; Li T; Wang LS; Obeid EI; Bleicher RJ; Eastwick G; Johnson ME; Hayes SB; Weiss SE; Anderson PR
Clin Breast Cancer; 2015 Oct; 15(5):381-9. PubMed ID: 25861716
[TBL] [Abstract][Full Text] [Related]
19. Use and Effectiveness of Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer in Men.
Venigalla S; Carmona R; Guttmann DM; Jain V; Freedman GM; Clark AS; Shabason JE
JAMA Oncol; 2018 Oct; 4(10):e181114. PubMed ID: 29800030
[TBL] [Abstract][Full Text] [Related]
20. Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer.
Tan X; Camacho F; Marshall VD; Donohoe J; Anderson RT; Balkrishnan R
Res Social Adm Pharm; 2017; 13(4):796-810. PubMed ID: 27641308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]